[Form 4] Rocket Pharmaceuticals, Inc. Insider Trading Activity
John Militello, Vice President of Finance, Treasurer and Principal Accounting Officer at Rocket Pharmaceuticals, Inc. (RCKT), reported two sales of common stock tied to RSU vesting. On 08/18/2025 he sold 699 shares at $3.065, leaving 56,285 shares beneficially owned. On 08/19/2025 he sold 361 shares at $2.996, leaving 55,924 shares owned. The filing states these shares were sold to pay tax withholding obligations related to Restricted Stock Units that convert one-for-one to common stock. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
John Militello, Vicepresidente della Finanza, Tesoriere e Responsabile Principale della Contabilit脿 di Rocket Pharmaceuticals, Inc. (RCKT), ha effettuato due vendite di azioni ordinarie relative al vesting di RSU. Il 18/08/2025 ha venduto 699 azioni a $3,065, rimanendo con la propriet脿 beneficiaria di 56.285 azioni. Il 19/08/2025 ha venduto 361 azioni a $2,996, portando il totale a 55.924 azioni possedute. La comunicazione indica che le azioni sono state vendute per assolvere obblighi fiscali collegati a Restricted Stock Units che si convertono uno a uno in azioni ordinarie. Il Modulo 4 猫 stato firmato da un procuratore il 20/08/2025.
John Militello, Vicepresidente de Finanzas, Tesorero y Oficial Principal de Contabilidad de Rocket Pharmaceuticals, Inc. (RCKT), inform贸 dos ventas de acciones ordinarias vinculadas al vesting de RSU. El 18/08/2025 惫别苍诲颈贸 699 acciones a $3.065, quedando con 56.285 acciones en propiedad beneficiaria. El 19/08/2025 惫别苍诲颈贸 361 acciones a $2.996, dejando 55.924 acciones en posesi贸n. La presentaci贸n indica que las acciones se vendieron para cubrir obligaciones fiscales relacionadas con Restricted Stock Units que se convierten una a una en acciones ordinarias. El Formulario 4 fue firmado por un apoderado el 20/08/2025.
John Militello, Rocket Pharmaceuticals, Inc. (RCKT)鞚� 鞛 攵�靷灔, 鞛雼措嫻 氚� 靾橃劃 須岅硠毂呾瀯鞛愲姅 RSU(鞝滍暅欤检嫕 雼渼) 甓岆Μ頇曥爼瓿� 甏�霠悳 氤错喌欤� 霊� 瓯挫潣 毵り皝鞚� 氤搓碃頄堨姷雼堧嫟. 2025-08-18鞐� 699欤�毳� 欤茧嫻 $3.065鞐� 毵る弰頃橃棳 56,285欤�鞚� 鞁れ 氤挫湢毳� 鞙犾頄堨姷雼堧嫟. 2025-08-19鞐愲姅 361欤�毳� 欤茧嫻 $2.996鞐� 毵る弰頃橃棳 氤挫湢欤检嫕鞚� 55,924欤�臧� 霅橃棃鞀惦媹雼�. 氤搓碃靹滌棎電� 鞚� 欤检嫕霌れ澊 鞚茧寑鞚茧 氤错喌欤茧 鞝勴櫂霅橂姅 Restricted Stock Units鞕� 甏�霠悳 鞗愳矞歆曥垬靹� 雮╇秬 鞚橂毳� 鞚错枆頃橁赴 鞙勴暣 毵り皝霅橃棃雼り碃 鞝來榾 鞛堨姷雼堧嫟. Form 4電� 2025-08-20鞐� 雽�毽澑鞐� 鞚橅暣 靹滊獏霅橃棃鞀惦媹雼�.
John Militello, Vice-Pr茅sident des Finances, Tr茅sorier et Responsable Comptable Principal chez Rocket Pharmaceuticals, Inc. (RCKT), a d茅clar茅 deux ventes d'actions ordinaires li茅es au vesting de RSU. Le 18/08/2025, il a vendu 699 actions 脿 3,065 $, restant titulaire b茅n茅ficiaire de 56 285 actions. Le 19/08/2025, il a vendu 361 actions 脿 2,996 $, laissant 55 924 actions en sa possession. Le d茅p么t indique que ces actions ont 茅t茅 vendues pour satisfaire des obligations fiscales li茅es 脿 des Restricted Stock Units qui se convertissent une pour une en actions ordinaires. Le formulaire 4 a 茅t茅 sign茅 par un mandataire le 20/08/2025.
John Militello, Vice President of Finance, Schatzmeister und Principal Accounting Officer bei Rocket Pharmaceuticals, Inc. (RCKT), meldete zwei Verk盲ufe von Stammaktien im Zusammenhang mit dem Vesting von RSUs. Am 18.08.2025 verkaufte er 699 Aktien zu $3,065, womit er 56.285 Aktien weiterhin wirtschaftlich besitzt. Am 19.08.2025 verkaufte er 361 Aktien zu $2,996, wodurch sich der Bestand auf 55.924 Aktien verringerte. Die Meldung gibt an, dass die Aktien verkauft wurden, um steuerliche Abzugspflichten im Zusammenhang mit Restricted Stock Units zu erf眉llen, die eins zu eins in Stammaktien umgewandelt werden. Das Formular 4 wurde am 20.08.2025 von einem Bevollm盲chtigten unterzeichnet.
- Transparent disclosure of dates, share amounts and prices for the sales
- Reason for sale provided (tax withholding related to RSU vesting), reducing potential misinterpretation
- Timely filing with signature provided by attorney-in-fact
- Insider sale of 1,060 shares reduces the reporting person's beneficial ownership from 56,285 to 55,924 shares
- Sales occurred at low prices (~$3.00), which could be viewed negatively by some investors despite being for tax withholding
Insights
TL;DR: Insider sales were executed to satisfy tax withholding on RSU vesting; transaction sizes are small relative to total shares outstanding.
The reported transactions are routine tax withholdings following RSU vesting rather than open-market disposals for other purposes. The total sold was 1,060 shares across two days at prices near $3.00. Such sales typically have limited informational content about company prospects but reduce the insider's post-transaction holdings modestly from 56,285 to 55,924 shares.
TL;DR: Filing shows timely disclosure and describes the sales as tax-withholding related, consistent with standard RSU practices.
The Form 4 discloses the reporting persons role and the reason for the sales (tax withholding for RSU vesting), which aligns with common disclosure practices. The document is signed by an attorney-in-fact, indicating proper execution. The transactions appear administrative in nature and the filing provides clear quantities, dates and prices for investor transparency.
John Militello, Vicepresidente della Finanza, Tesoriere e Responsabile Principale della Contabilit脿 di Rocket Pharmaceuticals, Inc. (RCKT), ha effettuato due vendite di azioni ordinarie relative al vesting di RSU. Il 18/08/2025 ha venduto 699 azioni a $3,065, rimanendo con la propriet脿 beneficiaria di 56.285 azioni. Il 19/08/2025 ha venduto 361 azioni a $2,996, portando il totale a 55.924 azioni possedute. La comunicazione indica che le azioni sono state vendute per assolvere obblighi fiscali collegati a Restricted Stock Units che si convertono uno a uno in azioni ordinarie. Il Modulo 4 猫 stato firmato da un procuratore il 20/08/2025.
John Militello, Vicepresidente de Finanzas, Tesorero y Oficial Principal de Contabilidad de Rocket Pharmaceuticals, Inc. (RCKT), inform贸 dos ventas de acciones ordinarias vinculadas al vesting de RSU. El 18/08/2025 惫别苍诲颈贸 699 acciones a $3.065, quedando con 56.285 acciones en propiedad beneficiaria. El 19/08/2025 惫别苍诲颈贸 361 acciones a $2.996, dejando 55.924 acciones en posesi贸n. La presentaci贸n indica que las acciones se vendieron para cubrir obligaciones fiscales relacionadas con Restricted Stock Units que se convierten una a una en acciones ordinarias. El Formulario 4 fue firmado por un apoderado el 20/08/2025.
John Militello, Rocket Pharmaceuticals, Inc. (RCKT)鞚� 鞛 攵�靷灔, 鞛雼措嫻 氚� 靾橃劃 須岅硠毂呾瀯鞛愲姅 RSU(鞝滍暅欤检嫕 雼渼) 甓岆Μ頇曥爼瓿� 甏�霠悳 氤错喌欤� 霊� 瓯挫潣 毵り皝鞚� 氤搓碃頄堨姷雼堧嫟. 2025-08-18鞐� 699欤�毳� 欤茧嫻 $3.065鞐� 毵る弰頃橃棳 56,285欤�鞚� 鞁れ 氤挫湢毳� 鞙犾頄堨姷雼堧嫟. 2025-08-19鞐愲姅 361欤�毳� 欤茧嫻 $2.996鞐� 毵る弰頃橃棳 氤挫湢欤检嫕鞚� 55,924欤�臧� 霅橃棃鞀惦媹雼�. 氤搓碃靹滌棎電� 鞚� 欤检嫕霌れ澊 鞚茧寑鞚茧 氤错喌欤茧 鞝勴櫂霅橂姅 Restricted Stock Units鞕� 甏�霠悳 鞗愳矞歆曥垬靹� 雮╇秬 鞚橂毳� 鞚错枆頃橁赴 鞙勴暣 毵り皝霅橃棃雼り碃 鞝來榾 鞛堨姷雼堧嫟. Form 4電� 2025-08-20鞐� 雽�毽澑鞐� 鞚橅暣 靹滊獏霅橃棃鞀惦媹雼�.
John Militello, Vice-Pr茅sident des Finances, Tr茅sorier et Responsable Comptable Principal chez Rocket Pharmaceuticals, Inc. (RCKT), a d茅clar茅 deux ventes d'actions ordinaires li茅es au vesting de RSU. Le 18/08/2025, il a vendu 699 actions 脿 3,065 $, restant titulaire b茅n茅ficiaire de 56 285 actions. Le 19/08/2025, il a vendu 361 actions 脿 2,996 $, laissant 55 924 actions en sa possession. Le d茅p么t indique que ces actions ont 茅t茅 vendues pour satisfaire des obligations fiscales li茅es 脿 des Restricted Stock Units qui se convertissent une pour une en actions ordinaires. Le formulaire 4 a 茅t茅 sign茅 par un mandataire le 20/08/2025.
John Militello, Vice President of Finance, Schatzmeister und Principal Accounting Officer bei Rocket Pharmaceuticals, Inc. (RCKT), meldete zwei Verk盲ufe von Stammaktien im Zusammenhang mit dem Vesting von RSUs. Am 18.08.2025 verkaufte er 699 Aktien zu $3,065, womit er 56.285 Aktien weiterhin wirtschaftlich besitzt. Am 19.08.2025 verkaufte er 361 Aktien zu $2,996, wodurch sich der Bestand auf 55.924 Aktien verringerte. Die Meldung gibt an, dass die Aktien verkauft wurden, um steuerliche Abzugspflichten im Zusammenhang mit Restricted Stock Units zu erf眉llen, die eins zu eins in Stammaktien umgewandelt werden. Das Formular 4 wurde am 20.08.2025 von einem Bevollm盲chtigten unterzeichnet.
FAQ
What did John Militello report on Form 4 for RCKT?
Why were the shares sold according to the filing?
How many shares does Militello beneficially own after the reported transactions?
Who signed the Form 4 and when?
Do the filings indicate these were RSU-related transactions?
